The market expects Arcturus Therapeutics (ARCT) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

View Our Latest Stock Analysis on ARCT Arcturus Therapeutics Stock Performance ARCT stock opened at $10.53 on Friday. The business has a 50-day simple moving average of $13.26 and a two-hundred ...

Arcturus Therapeutics Holdings Inc. ARCT announced ... NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base ...

Arcturus Therapeutics Holdings Inc is a biotechnology firm based in San Diego, California, specializing in the development of innovative mRNA medicines and vaccines. With a focus on addressing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...